Boston Scientific Corporation
BSX
$51.22
$0.761.50%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 46.67% | 75.44% | 56.40% | 55.66% | 37.04% |
| Total Depreciation and Amortization | 7.45% | 8.06% | 7.80% | 9.48% | 7.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -80.00% | -115.22% | -33.68% | -25.40% | -44.81% |
| Change in Net Operating Assets | -1,526.67% | -21.66% | 46.75% | 90.87% | 103.80% |
| Cash from Operations | 5.69% | 13.88% | 31.99% | 57.56% | 62.80% |
| Capital Expenditure | -13.00% | -8.52% | -10.89% | -2.82% | -1.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 81.65% | 61.15% | 65.67% | -144.27% | -552.36% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -871.95% | 104.41% | 33.46% | 55.19% | -28.13% |
| Cash from Investing | 47.30% | 53.73% | 53.58% | -92.09% | -274.14% |
| Total Debt Issued | -4.07% | -99.94% | -33.15% | -18.60% | -17.17% |
| Total Debt Repaid | 57.17% | 23.95% | -287.33% | -247.83% | -204.88% |
| Issuance of Common Stock | -18.45% | -6.42% | 22.61% | 32.42% | 36.87% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 43.17% | 36.65% | 14.61% | 12.27% | -86.58% |
| Cash from Financing | -940.35% | -285.77% | -121.78% | -99.81% | -92.98% |
| Foreign Exchange rate Adjustments | -94.74% | -91.43% | 481.82% | 1,400.00% | 522.22% |
| Miscellaneous Cash Flow Adjustments | 100.00% | 0.00% | -- | -- | -200.00% |
| Net Change in Cash | 100.52% | 145.88% | 442.44% | -177.39% | -195.05% |